RESULTS:

The failure of solid tumors to respond to chemotherapy is a complicated and clinically frustrating issue. The ability to predict which tumors will respond to treatment could reduce the human and monetary costs of cancer therapy by allowing pro-active selection of a chemotherapeutic to which the tumor does not express resistance. PET/CT imaging with a radiolabeled form of paclitaxel F-18 fluoropaclitaxel (FPAC) may be able to predict the uptake of paclitaxel in solid tumors and as a substrate of P-glycoprotein it may also predict which tumors exhibit multidrug resistance (MDR) a phenotype in which tumors fail to respond to a wide variety of chemically unrelated chemotherapeutic agents. This article reviews the synthetic preclinical and early human data obtained during the development phase of this promising new radiopharmaceutical.